Andrew Mesecar named director of Purdue Institute for Cancer Research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Andrew Mesecar, Distinguished Professor of Biochemistry and the Walther Professor in Cancer Structural Biology, was named assistant vice president for research and director of the Purdue Institute for Cancer Research after serving, since Aug. 2022, as interim director. Mesecar was chosen for the position after a nationwide search.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Positive high-level results showed Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival versus trastuzumab emtansine in patients with HER2-positive early breast cancer with residual invasive disease in the breast or axillary lymph nodes after neoadjuvant treatment and a high-risk of disease recurrence, according to a planned interim analysis of the DESTINY-Breast05 phase III trial. 
Positive high-level results from the Tropion-Breast02 phase III trial showed Datroway (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival compared to investigator’s choice of chemotherapy as first-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer for whom immunotherapy was not an option.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login